Vermillion Inc (VRML) 1.08 $VRML
Vermillion reports 1Q loss
Automated Insights - Mon May 16, 3:07PM CDT
AUSTIN, Texas (AP) _ Vermillion Inc. (VRML) on Monday reported a loss of $4.9 million in its first quarter.
VRML: 1.08 (+0.01)
Vermillion Reports First Quarter 2016 Results
PR Newswire - Mon May 16, 3:01PM CDT
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial results for the first quarter ended March 31, 2016.
VRML: 1.08 (+0.01)
Vermillion to Showcase Comparison of Overa(TM) and ROMA(TM) Algorithms at ACOG 2016 Annual Meeting
PR Newswire - Mon May 16, 8:00AM CDT
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company today announced positive top line results from a study entitled, "Clinical Performance Comparison of Two IVDMIAs for Pre-Surgical Assessment of Ovarian Cancer Risk", presented at the annual meeting of American Congress of Obstetricians and Gynecologists (ACOG), taking place May 14th thru May 17th in Washington DC. Overa(TM) is Vermillion's FDA-cleared second-generation version of the OVA1 blood test, used for pre-surgical assessment of ovarian cancer risk in women undergoing surgery for an ovarian (adnexal) mass. ROMA(TM) (Risk of Ovarian Malignancy Algorithm) is the only other ovarian cancer triage test that has been cleared by FDA.
VRML: 1.08 (+0.01)
Vermillion to Report First Quarter 2016 Financial Results and Host Investor Conference Call on May 16
PR Newswire - Mon May 02, 3:05PM CDT
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its first quarter 2016 financial results on Monday, May 16, 2016, followed by an investor conference call and webcast at 4:30pm Eastern.
VRML: 1.08 (+0.01)
Vermillion Announces Publication of First OVA1(R) Clinical Utility Study
GlobeNewswire - Tue Apr 19, 3:01PM CDT
Vermillion, Inc. (NASDAQ:VRML), a bio-analytical solutions company focused on gynecologic disease, today announced the publication of the first clinical utility data demonstrating that identification of high-risk patients using OVA1 prior to surgery resulted in referral of nearly all patients who had primary ovarian malignancies to gynecologic oncologists. The study, titled "The clinical utility of an elevated-risk multivariate index assay score measured by pre-surgical involvement of gynecologic oncologists in the management of ovarian cancer," to be published in the peer-reviewed journal Current Medical Research & Opinion (CMRO), is now available online as a pre-print (DOI: 10.1080/03007995.2016.1176014).
VRML: 1.08 (+0.01)
Vermillion Receives $2 Million Disbursement of up to $4 Million Loan from the Connecticut Department of Economic and Community Development
GlobeNewswire - Mon Apr 18, 3:01PM CDT
Vermillion, Inc. (NASDAQ:VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that the Company has executed a loan of up to $4,000,000 from the Connecticut Department of Economic and Community Development (DECD). Proceeds from the 10-year loan, which bears interest at a fixed rate of 2.0% per annum, will be primarily utilized to fund the build-out of Vermillion's Trumbull, CT facility including investment in laboratory services and information technology infrastructure.
VRML: 1.08 (+0.01)
Vermillion Reports Fourth Quarter and Full Year 2015 Results
PR Newswire - Thu Mar 24, 7:00AM CDT
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its results for the fourth quarter and full year ended December 31, 2015.
VRML: 1.08 (+0.01)
/C O R R E C T I O N -- Vermillion, Inc./
PR Newswire - Mon Mar 21, 8:57AM CDT
In the news release, Vermillion Announces FDA Clearance of Overa®, Second Generation OVA1® Test, issued 21-Mar-2016 by Vermillion, Inc. over PR Newswire, we are advised by the company that the quote in the fourth paragraph was incorrect. The complete, corrected release follows:
VRML: 1.08 (+0.01)
Vermillion Announces Date Change for Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Mon Mar 21, 8:30AM CDT
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today it will report its fourth quarter and full year 2015 financial results on Thursday, March 24, 2016, followed by an investor conference call and webcast at 8:30am Eastern.
VRML: 1.08 (+0.01)
Vermillion Announces FDA Clearance of Overa®, Second Generation OVA1® Test
PR Newswire - Mon Mar 21, 7:15AM CDT
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today the receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for the successor to Vermillion's OVA1® test for determining ovarian cancer risk in conjunction with independent clinical and imaging assessment prior to planned surgery for a women with a pelvic mass. The Second Generation OVA1 test, previously referred to as "OVA2", has been trademarked "Overa®."
VRML: 1.08 (+0.01)
Vermillion to Report Fourth Quarter and Full Year 2015 Financial Results and Host Investor Conference Call on March 30
PR Newswire - Tue Mar 15, 8:00AM CDT
Vermillion, Inc. (VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its fourth quarter and full year 2015 financial results on Wednesday, March 30, 2016, followed by an investor conference call and webcast at 8:30am Eastern.
VRML: 1.08 (+0.01)
National Academy of Medicine Ovarian Cancer Report Ignites Reaction from Vermillion & OVA1® Awareness Team
PR Newswire - Fri Mar 11, 10:00AM CST
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, responded to the National Academy of Medicine (NAM) March report on ovarian cancer by launching a first of its kind pelvic mass website www.KnowPelvicMass.com along with a national advertising campaign debuting in USA TODAY on March 11th which spotlights pelvic mass.
VRML: 1.08 (+0.01)
Vermillion Lands America's Most Decorated Gymnast and Ovarian Cancer Survivor, Shannon Miller, for its OVA1® Awareness Team
PR Newswire - Tue Feb 09, 8:00AM CST
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced the most decorated gymnast in American history has joined its new OVA1 Awareness Team. As a member of Vermillion's Awareness Team, Shannon Miller will be tasked with "spring boarding" an ongoing dialogue about pelvic masses, the signs and symptoms of ovarian cancer, along with the use of the OVA1 blood test. OVA1 is the first FDA-cleared blood test used to evaluate the cancer risk of a pelvic mass. Shannon is an ovarian cancer survivor, an accomplished author, an entrepreneur and a champion gymnast who has earned seven Olympic medals.
VRML: 1.08 (+0.01)
United States Fiber Optic Cable Market 2016 - Analysis And Forecast to 2020
M2 - Thu Jan 21, 4:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/rft9ng/u_s_fiber_optic) has announced the addition of the "U.S. Fiber Optic Cable Market - Analysis And Forecast to 2020" report to their offering. The report provides an in-depth analysis of the U.S. Fiber Optic Cable market. It presents the latest data of the market size and volume, domestic production, exports and imports, price dynamics and turnover in the industry. In addition, the report contains insightful information about the industry, including industry life cycle, business locations, productivity, employment and many other crucial aspects. The Company Profiles section contains relevant data on the major players in the industry. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Market Overview 4. Domestic Production 5. Imports 6. Exports 7. Competitive Landscape 8. Company Profiles - W. L. Gore & Associates - Superior Essex - Optical Cable Corporation - Essex Group - US Conec - Fiberdyne Labs - Nistica - Broadata Communications - United Copper Industries - Nexans USA - California Insulated Wire & Cable - Marmon Utility - TLC-The Light Connection - Stonewall Cable - Mercury Wire Products - Applied Fiber Telecommunications - Vermillion Incorporated - Salt Lake Cable & Harness - American Furukawa - Rochester Wire and Cable - Mackin Technologies - Draka Holdings Usa - Applied Optical Systems - Sensors Unlimited - Isotec - Xponet - Ofs Brightwave - Tyco Electronics Integrated Cable Systems - American Insulated Wire Corporation - Precision Utilities Group - Allwire - Noma Corporation - Superior Essex International - UCI Holdings For more information visit http://www.researchandmarkets.com/research/rf...iber_optic
OCC: 2.27 (+0.01), TEL: 57.53 (+1.11), VRML: 1.08 (+0.01)
Vermillion to Present at 7th Annual Life Science CEO Forum
PR Newswire - Tue Jan 19, 8:00AM CST
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that it will present at the 7th Annual Life Science CEO Forum on January 25-26 in Atlanta GA at the Westin Buckhead Hotel. Valerie Palmieri, President and Chief Executive Officer of Vermillion, will present on "The Plight of Ovarian Cancer, a Pelvic Mass Care Pathway Solution and Getting Paid," highlighting the use of Vermillion's OVA1® diagnostic test, at 5:00 PM EST on January 25th. Ms. Palmieri will be joined in the conference by speakers representing such diverse companies as Genzyme, J&J, Pfizer and Sun Pharma.
VRML: 1.08 (+0.01)
Vermillion to Host Key Opinion Leader Meeting to Discuss Advances in Ovarian Cancer Detection
PR Newswire - Wed Dec 09, 12:19PM CST
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that it will host a Key Opinion Leader breakfast on Friday, December 11, 2015 from 8am-9:30am Eastern Time in New York City.
VRML: 1.08 (+0.01)
Story Behind the Charts - Research on Vermillion, Bridgford Foods, Symmetry Surgical and SCYNEXIS
ACCESSWIRE - Wed Dec 02, 7:20AM CST
NEW YORK, NY / ACCESSWIRE / December 02, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Vermillion Inc. (NASDAQ: VRML), Bridgford Foods Corp. (NASDAQ: BRID), Symmetry Surgical Inc. (NASDAQ: SSRG) and SCYNEXIS Inc. (NASDAQ: SCYX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
SCYX: 2.21 (+0.03), BRID: 13.71 (+0.14), SSRG: 13.18 (+0.05), VRML: 1.08 (+0.01)
Vermillion Announces Key Medical Policy Coverage by Medi-Cal for OVA1® Test
PR Newswire - Tue Dec 01, 8:00AM CST
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced additional medical policy coverage for OVA1, with Medi-Cal, California's Medicaid program. Medi-Cal is now supporting OVA1 in its medical policy guidelines. Medi-Cal covers over 12.6 million beneficiaries, which represent approximately a third of the covered lives in California.
VRML: 1.08 (+0.01)
Vermillion to Present Corporate Overview at the Canaccord Genuity Medical Technology & Diagnostics Forum
PR Newswire - Tue Nov 17, 8:00AM CST
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that Valerie Palmieri, President and Chief Executive Officer of Vermillion, Inc., will present a corporate overview at the Canaccord Genuity Medical Technology & Diagnostics Forum.
VRML: 1.08 (+0.01)
Vermillion reports 1Q loss
Automated Insights - Mon May 16, 3:07PM CDT
AUSTIN, Texas (AP) _ Vermillion Inc. (VRML) on Monday reported a loss of $4.9 million in its first quarter.
VRML: 1.08 (+0.01)
Vermillion Reports First Quarter 2016 Results
PR Newswire - Mon May 16, 3:01PM CDT
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial results for the first quarter ended March 31, 2016.
VRML: 1.08 (+0.01)
Vermillion to Showcase Comparison of Overa(TM) and ROMA(TM) Algorithms at ACOG 2016 Annual Meeting
PR Newswire - Mon May 16, 8:00AM CDT
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company today announced positive top line results from a study entitled, "Clinical Performance Comparison of Two IVDMIAs for Pre-Surgical Assessment of Ovarian Cancer Risk", presented at the annual meeting of American Congress of Obstetricians and Gynecologists (ACOG), taking place May 14th thru May 17th in Washington DC. Overa(TM) is Vermillion's FDA-cleared second-generation version of the OVA1 blood test, used for pre-surgical assessment of ovarian cancer risk in women undergoing surgery for an ovarian (adnexal) mass. ROMA(TM) (Risk of Ovarian Malignancy Algorithm) is the only other ovarian cancer triage test that has been cleared by FDA.
VRML: 1.08 (+0.01)
Vermillion to Report First Quarter 2016 Financial Results and Host Investor Conference Call on May 16
PR Newswire - Mon May 02, 3:05PM CDT
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its first quarter 2016 financial results on Monday, May 16, 2016, followed by an investor conference call and webcast at 4:30pm Eastern.
VRML: 1.08 (+0.01)
Vermillion Announces Publication of First OVA1(R) Clinical Utility Study
GlobeNewswire - Tue Apr 19, 3:01PM CDT
Vermillion, Inc. (NASDAQ:VRML), a bio-analytical solutions company focused on gynecologic disease, today announced the publication of the first clinical utility data demonstrating that identification of high-risk patients using OVA1 prior to surgery resulted in referral of nearly all patients who had primary ovarian malignancies to gynecologic oncologists. The study, titled "The clinical utility of an elevated-risk multivariate index assay score measured by pre-surgical involvement of gynecologic oncologists in the management of ovarian cancer," to be published in the peer-reviewed journal Current Medical Research & Opinion (CMRO), is now available online as a pre-print (DOI: 10.1080/03007995.2016.1176014).
VRML: 1.08 (+0.01)
Vermillion Receives $2 Million Disbursement of up to $4 Million Loan from the Connecticut Department of Economic and Community Development
GlobeNewswire - Mon Apr 18, 3:01PM CDT
Vermillion, Inc. (NASDAQ:VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that the Company has executed a loan of up to $4,000,000 from the Connecticut Department of Economic and Community Development (DECD). Proceeds from the 10-year loan, which bears interest at a fixed rate of 2.0% per annum, will be primarily utilized to fund the build-out of Vermillion's Trumbull, CT facility including investment in laboratory services and information technology infrastructure.
VRML: 1.08 (+0.01)
Vermillion Reports Fourth Quarter and Full Year 2015 Results
PR Newswire - Thu Mar 24, 7:00AM CDT
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its results for the fourth quarter and full year ended December 31, 2015.
VRML: 1.08 (+0.01)
/C O R R E C T I O N -- Vermillion, Inc./
PR Newswire - Mon Mar 21, 8:57AM CDT
In the news release, Vermillion Announces FDA Clearance of Overa®, Second Generation OVA1® Test, issued 21-Mar-2016 by Vermillion, Inc. over PR Newswire, we are advised by the company that the quote in the fourth paragraph was incorrect. The complete, corrected release follows:
VRML: 1.08 (+0.01)
Vermillion Announces Date Change for Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Mon Mar 21, 8:30AM CDT
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today it will report its fourth quarter and full year 2015 financial results on Thursday, March 24, 2016, followed by an investor conference call and webcast at 8:30am Eastern.
VRML: 1.08 (+0.01)
Vermillion Announces FDA Clearance of Overa®, Second Generation OVA1® Test
PR Newswire - Mon Mar 21, 7:15AM CDT
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today the receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for the successor to Vermillion's OVA1® test for determining ovarian cancer risk in conjunction with independent clinical and imaging assessment prior to planned surgery for a women with a pelvic mass. The Second Generation OVA1 test, previously referred to as "OVA2", has been trademarked "Overa®."
VRML: 1.08 (+0.01)
Vermillion to Report Fourth Quarter and Full Year 2015 Financial Results and Host Investor Conference Call on March 30
PR Newswire - Tue Mar 15, 8:00AM CDT
Vermillion, Inc. (VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its fourth quarter and full year 2015 financial results on Wednesday, March 30, 2016, followed by an investor conference call and webcast at 8:30am Eastern.
VRML: 1.08 (+0.01)
National Academy of Medicine Ovarian Cancer Report Ignites Reaction from Vermillion & OVA1® Awareness Team
PR Newswire - Fri Mar 11, 10:00AM CST
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, responded to the National Academy of Medicine (NAM) March report on ovarian cancer by launching a first of its kind pelvic mass website www.KnowPelvicMass.com along with a national advertising campaign debuting in USA TODAY on March 11th which spotlights pelvic mass.
VRML: 1.08 (+0.01)
Vermillion Lands America's Most Decorated Gymnast and Ovarian Cancer Survivor, Shannon Miller, for its OVA1® Awareness Team
PR Newswire - Tue Feb 09, 8:00AM CST
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced the most decorated gymnast in American history has joined its new OVA1 Awareness Team. As a member of Vermillion's Awareness Team, Shannon Miller will be tasked with "spring boarding" an ongoing dialogue about pelvic masses, the signs and symptoms of ovarian cancer, along with the use of the OVA1 blood test. OVA1 is the first FDA-cleared blood test used to evaluate the cancer risk of a pelvic mass. Shannon is an ovarian cancer survivor, an accomplished author, an entrepreneur and a champion gymnast who has earned seven Olympic medals.
VRML: 1.08 (+0.01)
United States Fiber Optic Cable Market 2016 - Analysis And Forecast to 2020
M2 - Thu Jan 21, 4:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/rft9ng/u_s_fiber_optic) has announced the addition of the "U.S. Fiber Optic Cable Market - Analysis And Forecast to 2020" report to their offering. The report provides an in-depth analysis of the U.S. Fiber Optic Cable market. It presents the latest data of the market size and volume, domestic production, exports and imports, price dynamics and turnover in the industry. In addition, the report contains insightful information about the industry, including industry life cycle, business locations, productivity, employment and many other crucial aspects. The Company Profiles section contains relevant data on the major players in the industry. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Market Overview 4. Domestic Production 5. Imports 6. Exports 7. Competitive Landscape 8. Company Profiles - W. L. Gore & Associates - Superior Essex - Optical Cable Corporation - Essex Group - US Conec - Fiberdyne Labs - Nistica - Broadata Communications - United Copper Industries - Nexans USA - California Insulated Wire & Cable - Marmon Utility - TLC-The Light Connection - Stonewall Cable - Mercury Wire Products - Applied Fiber Telecommunications - Vermillion Incorporated - Salt Lake Cable & Harness - American Furukawa - Rochester Wire and Cable - Mackin Technologies - Draka Holdings Usa - Applied Optical Systems - Sensors Unlimited - Isotec - Xponet - Ofs Brightwave - Tyco Electronics Integrated Cable Systems - American Insulated Wire Corporation - Precision Utilities Group - Allwire - Noma Corporation - Superior Essex International - UCI Holdings For more information visit http://www.researchandmarkets.com/research/rf...iber_optic
OCC: 2.27 (+0.01), TEL: 57.53 (+1.11), VRML: 1.08 (+0.01)
Vermillion to Present at 7th Annual Life Science CEO Forum
PR Newswire - Tue Jan 19, 8:00AM CST
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that it will present at the 7th Annual Life Science CEO Forum on January 25-26 in Atlanta GA at the Westin Buckhead Hotel. Valerie Palmieri, President and Chief Executive Officer of Vermillion, will present on "The Plight of Ovarian Cancer, a Pelvic Mass Care Pathway Solution and Getting Paid," highlighting the use of Vermillion's OVA1® diagnostic test, at 5:00 PM EST on January 25th. Ms. Palmieri will be joined in the conference by speakers representing such diverse companies as Genzyme, J&J, Pfizer and Sun Pharma.
VRML: 1.08 (+0.01)
Vermillion to Host Key Opinion Leader Meeting to Discuss Advances in Ovarian Cancer Detection
PR Newswire - Wed Dec 09, 12:19PM CST
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that it will host a Key Opinion Leader breakfast on Friday, December 11, 2015 from 8am-9:30am Eastern Time in New York City.
VRML: 1.08 (+0.01)
Story Behind the Charts - Research on Vermillion, Bridgford Foods, Symmetry Surgical and SCYNEXIS
ACCESSWIRE - Wed Dec 02, 7:20AM CST
NEW YORK, NY / ACCESSWIRE / December 02, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Vermillion Inc. (NASDAQ: VRML), Bridgford Foods Corp. (NASDAQ: BRID), Symmetry Surgical Inc. (NASDAQ: SSRG) and SCYNEXIS Inc. (NASDAQ: SCYX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
SCYX: 2.21 (+0.03), BRID: 13.71 (+0.14), SSRG: 13.18 (+0.05), VRML: 1.08 (+0.01)
Vermillion Announces Key Medical Policy Coverage by Medi-Cal for OVA1® Test
PR Newswire - Tue Dec 01, 8:00AM CST
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced additional medical policy coverage for OVA1, with Medi-Cal, California's Medicaid program. Medi-Cal is now supporting OVA1 in its medical policy guidelines. Medi-Cal covers over 12.6 million beneficiaries, which represent approximately a third of the covered lives in California.
VRML: 1.08 (+0.01)
Vermillion to Present Corporate Overview at the Canaccord Genuity Medical Technology & Diagnostics Forum
PR Newswire - Tue Nov 17, 8:00AM CST
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that Valerie Palmieri, President and Chief Executive Officer of Vermillion, Inc., will present a corporate overview at the Canaccord Genuity Medical Technology & Diagnostics Forum.
VRML: 1.08 (+0.01)
